tilsotolimod + pembrolizumab

Tilsotolimod + pembrolizumab is an investigational **combination regimen** of two distinct agents for oncology: - **Tilsotolimod** (IMO-2125) is a synthetic oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist designed to activate innate immune responses, leading to recruitment and activation of dendritic cells and enhancement of tumor-specific T-cell responses. - **Pembrolizumab** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as a checkpoint inhibitor to potentiate anti-tumor T cell responses. This combination has been explored in early-phase clinical trials for advanced/metastatic melanoma, particularly in patients who experienced progression with previous PD-1 inhibitor therapy. The specific trial cohort combining tilsotolimod with pembrolizumab was discontinued following phase 1, with the majority of the program shifting to combinations with ipilimumab[1][5].

Other names

tilsotolimodIMO-2125IMO2125IMO 2125pembrolizumab